ZenBio, Inc. Awarded a Phase I SBIR Grant to Develop Novel Human Cell-Based Models of Fatty Liver Disease
4/21/2010 11:55:11 AM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--ZenBio, Inc. announced that it has been awarded a Phase I SBIR grant to establish novel human cell-based models of non-alcoholic fatty liver disease (NAFLD) that will be useful for basic research and as a potential drug development platform. The project stems from recent efforts at ZenBio, Inc. to develop methods for differentiating adipose tissue derived progenitor cells into hepatocyte-like cells. The current award from the National Institutes of Health will fund proof-of-concept studies that these human hepatocyte-like cells can be used to mimic the development of non-alcoholic fatty liver disease in cell culture.
comments powered by